Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy In Incident Haemodialysis Patients

Trial Profile

UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy In Incident Haemodialysis Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Iron sucrose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms PIVOTAL
  • Most Recent Events

    • 02 Nov 2018 New trial record
    • 29 Oct 2018 According to a Vifor Pharma media release, results from this trial were published online in The New England Journal of Medicine
    • 29 Oct 2018 Primary endpoint has been met. (Time to all-cause death or a composite of non-fatal cardiovascular events (myocardial infarction, stroke, and hospitalisation for heart failure) adjudicated by a blinded Endpoint Adjudication Committee.), according to a Vifor Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top